Accelerating Oncology Specialty Drug Prior Auth with Intelligent Automation

Klivira's platform is engineered to navigate the intricate landscape of oncology specialty drug prior auth, minimizing administrative burden and accelerating critical time-to-treatment for cancer patients.

For revenue cycle directors and prior authorization coordinators in cancer care, managing specialty drug PAs is a high-stakes, high-volume challenge. The complexity of oncology regimens, coupled with the dual medical and pharmacy benefit pathways, frequently leads to delays that can impact patient outcomes.

The Unique Demands of Oncology Specialty Drug Prior Auth

Oncology workflows present a unique prior authorization burden due to high-cost biologics, infusion therapies, radiation oncology, and frequent regimen changes. A single patient often requires dozens of PA events across diagnosis, staging, multiple lines of treatment, supportive care, and surveillance, making efficient management critical for both financial health and patient outcomes.

Key Prior Authorization Triggers in Oncology

J-code chemotherapy and biologic infusions (e.g., immunotherapies, targeted therapies, antibody-drug conjugates)
Advanced imaging for staging and surveillance (e.g., PET/CT, advanced MRI, tumor-specific molecular imaging)
Radiation oncology procedures (e.g., IMRT, IGRT, SBRT, brachytherapy, proton-beam therapy)
Genetic and molecular testing for treatment selection and risk stratification (e.g., NGS panels, single-gene tests)
Supportive care medications (e.g., growth factors, ESAs, antiemetics, bone-targeting agents)

Navigating Medical vs. Pharmacy Benefit for Oncology Drugs

Oncology drugs are distinctly split between the medical benefit (provider-administered IV therapies) and the pharmacy benefit (patient-administered oral oncolytics). This split dictates separate PA pathways: medical benefit PAs route through payer portals or X12 278, while pharmacy benefit PAs route through PBMs and ePA partners like CoverMyMeds or Surescripts using NCPDP SCRIPT. Klivira automates this benefit-side determination and multi-channel routing.

Critical Documentation for Oncology Drug Prior Authorizations

Diagnosis confirmation, including pathology report, AJCC TNM staging, and relevant molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1, BRCA, MSI/MMR)
Prior-line treatment response and rationale for subsequent regimens, including duration of response and reason for change
Performance status (e.g., ECOG or Karnofsky score) to support fitness for proposed treatment
Comorbidities and contraindications, including organ function and prior toxicities
NCCN Compendium citation (Category 1, 2A, or 2B) for off-label drug use, specifying tumor type and clinical context

Klivira's Intelligent Approach to Oncology Specialty Drug PA

Klivira's platform is designed to address the unique challenges of oncology specialty drug prior authorization. Our NCCN-compendium-aware policy logic surfaces required documentation at the point of order entry. We enable regimen-level PA workflows, manage the medical-vs-pharmacy benefit split, and provide concurrent PA tracking for the numerous authorization events per patient. Klivira also supports peer-to-peer scheduling integration for clinical-necessity denials and automates step-therapy documentation using FHIR-based clinical data.

Integrating with EMRs and Payer Channels for Seamless Workflows

Klivira integrates with your existing EMR systems, leveraging standards like SMART on FHIR to extract critical clinical data, such as medication history and treatment response, directly into PA requests. Our platform connects to diverse payer channels, including X12 278, Da Vinci PAS, and NCPDP SCRIPT ePA, ensuring efficient, compliant submission and real-time status updates across all oncology prior authorization types.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for oncology drugs?

Klivira's policy engine automatically determines the correct benefit side (medical or pharmacy) for each oncology drug, per payer and patient context. It then routes submissions through the appropriate channel, utilizing NCPDP SCRIPT ePA for pharmacy benefits and X12 278 or Da Vinci PAS for medical benefits.

What specific oncology documentation requirements does Klivira support?

Klivira's NCCN-compendium-aware logic guides users on required documentation like pathology reports, tumor staging, molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), prior-line treatment history, and performance status (ECOG/Karnofsky). It helps ensure all necessary clinical data is included for submission.

How does Klivira address the urgency of oncology treatment initiation?

Klivira streamlines the prior authorization process by automating benefit-side determination, populating clinical data from the EMR, and routing submissions efficiently. This reduces administrative delays, helping accelerate the diagnosis-to-treatment interval, which is crucial in many aggressive cancer types.

Can Klivira integrate with our existing EMR for oncology PA?

Yes, Klivira integrates with major EMR systems using standards like SMART on FHIR. This allows for automated extraction of relevant clinical data, such as medication history and treatment response, directly from the EMR to pre-populate PA requests for oncology drugs.

How does Klivira manage frequent regimen changes and multiple PAs per patient?

Klivira supports regimen-level PA workflows, bundling related components where payers allow, and provides concurrent PA tracking for the numerous authorization events an oncology patient may require over their treatment course, including supportive care and surveillance imaging.